Kyowa Hakko Kirin launches Nauzelin OD tablet formulation
The Nauzelin OD Tablets formulation includes Nauzelin OD Tablets 5 and Nauzelin OD Tablets 10. The new Nauzelin orally disintegrating tablet formulation has been developed by Kyowa Hakko
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
The collaboration is intended to evaluate the utility of Daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, along with Tibotec Pharmaceuticals’ NS3 protease inhibitor, TMC435, for the